课题基金 / 基金详情

TAMOXIFEN AND 9 CIS RETINOIC ACID IN ADVANCED BREAST CANCER

TAMOXIFEN AND 9 CIS RETINOIC ACID IN ADVANCED BREAST CANCER
他莫昔芬和 9 顺式维甲酸治疗晚期乳腺癌
批准号：
6305874
负责人：
CAROLYN WASSERHEIT
金额：
$2.1万
依托单位：
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
依托单位国家：
美国
项目类别：
财政年份：
1999
资助国家：
美国
项目状态：
已结题
起止时间：
1999-12-01 至 2000-11-30
来源：
https://reporter.nih.gov/project-details/6305874
关键词：
breast neoplasms clinical research clinical trial phase I combination chemotherapy drug screening /evaluation female human subject human therapy evaluation neoplasm /cancer chemotherapy pharmacokinetics retinoate tamoxifen

项目摘要

项目成果

CAROLYN WASSERHEIT的其他基金

相似基金

相关文献

中文摘要
翻译
这项I期试验将试图确定标准剂量他莫昔芬与9-顺式维甲酸联合使用的最大耐受剂量和药代动力学。剂量限制性毒性、反应率、反应持续时间和生存期将被确定。将对患者原发和转移性肿瘤组织中维甲酸受体、类维甲酸X受体和类维甲酸孤儿受体mRNA和蛋白的各种亚型的水平进行表征。核心实验室生产、纯化并滴度了一种表达维甲酸受体的腺病毒载体，用于与乳腺癌相关的临床前研究。利用核心实验室进行层流罩和重组DNA技术的使用。
英文摘要
This Phase I trial will attempt to determine the maximally tolerated dose and pharmacokinetics of a combination of standard dose tamoxifen with 9-cis retinoic acid. Dose-limiting toxicity, response rate, duration of response, and survival will be determined. Levels of the various subtypes of retinoic acid receptors, retinoid X receptor, and retinoid orphan receptor mRNA and protein in tissue derived from the patient's primary and metastatic tumors will be characterized. The Core Laboratory has produced, purified, and titered an adenovirus vector expressing the retinoic acid receptor for preclinical studies relevant to breast cancer. The Core Laboratory was utilized for use of laminar flow hoods and recombinant DNA Techniques.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
DOXIL & TAXOTERE IN PATIENTS W/ ADVANCED MALIGNANCIES
DOXIL & TAXOTERE IN PATIENTS W/ ADVANCED MALIGNANCIES
TAMOXIFEN AND 9 CIS RETINOIC ACID IN ADVANCED BREAST CANCER
DOXORUBICIN AND EDATREXATE IN THE TREATMENT OF SOLID TUMORS
海外基金